BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025
Rhea-AI Summary
BrainsWay (NASDAQ: BWAY) will report third quarter 2025 financial results and operational highlights before U.S. market open on Tuesday, November 11, 2025. The company will host a conference call and webcast at 8:30 AM ET to discuss results and business updates.
Dial-in numbers, conference ID 10203968, and a live webcast will be available; the replay will be posted on the investor website for 30 days. Investors are asked to register at least 10 minutes early.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, BWAY declined 2.50%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, November 11, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the financial results and provide an update on business operations.
Conference Call Dial-In & Webcast Information
| Date: | Tuesday, November 11, 2025 |
| Time: | 8:30 AM Eastern Time |
| United States: | 1-877-300-8521 |
| International: | 1-412-317-6026 |
| Israel: | 1-80-921-2373 |
| Conference ID: | 10203968 |
| Webcast: | Link |
The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Company’s website at least 10 minutes ahead of the conference call to register.
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
Contacts:
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com
Investors:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
FAQ
When will BrainsWay (BWAY) report third quarter 2025 results?
What time is the BrainsWay (BWAY) conference call and webcast on November 11, 2025?
How can investors join the BrainsWay (BWAY) conference call on November 11, 2025?
Will the BrainsWay (BWAY) webcast be available after the call?
Where can I find the BrainsWay (BWAY) webcast link and replay?
